---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-23-000057"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:40:20.141579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora's KIO-301 shows vision restoration in blind RP patients in Phase 1b

## Summary
- Preliminary Phase 1b ABACUS data: KIO-301 improved light perception in patients with no light perception.
- Patient-reported light/dark contrast perception improved at days 7, 14, and 29 post-injection.
- fMRI showed significantly increased V1 visual cortex activity at days 3 and 15 vs. baseline.
- Quality-of-life score increased 6 points (clinically meaningful threshold is 2–4 points).
- No adverse events reported; dose escalation and full results expected later in 2023.

## SEC filing metadata
- accession: 0001372514-23-000057
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000057/0001372514-23-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251423000057/kprx-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-23-000057
- JSON: https://secwatch.observer/filing/0001372514-23-000057.json
- Plain text: https://secwatch.observer/filing/0001372514-23-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.